INCOG BioPharma
Overview
INCOG BioPharma Services, founded in 2020 by Cory Lewis and Tedd Green, is a leading Contract Development and Manufacturing Organization (CDMO) specializing in sterile injectable biopharmaceuticals. Based in Fishers, Indiana, the company has raised $42.9 million across various funding rounds. INCOG is designed to provide end-to-end solutions for the development and manufacturing of injectable drug products, offering comprehensive services from formulation to final packaging.
Recent Developments
- July 2024: INCOG BioPharma announced a $125 million investment to expand its manufacturing capabilities in Fishers, Indiana, including constructing a second 100,000-square-foot facility. This expansion aims to enhance production capacities for autoinjectors and syringe accessorizing, creating over 100 jobs and further establishing Fishers as a biopharmaceutical hub.
- February 2024: The company added an additional 100 million units of syringe and cartridge filling capacity by integrating a high-speed OPTIMA filling line. This expansion is set to commence GMP production by the second quarter of 2025.
- April 2023: INCOG received the Best Places to Work award from the Indiana Chamber of Commerce for its positive workplace culture and significant contributions to the biopharmaceutical industry.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2020 |
| Headquarters | Fishers, Indiana, USA |
| Founders | Cory Lewis, Tedd Green |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Presidio Partners, Trinity Capital |
| Industry | Biotechnology, CDMO |
| Number of Employees | 140 as of 2024 |
Early History
INCOG BioPharma Services was established during the turbulent year of 2020, inspired during a bicycle ride in Maui by Cory Lewis, who decided to leverage his extensive CDMO experience. Together with Tedd Green, they founded INCOG with the vision to provide better customer-centric CDMO services. The company quickly became a notable player in the biopharma sector by investing in state-of-the-art facilities and equipment, allowing it to handle both clinical and commercial scale productions efficiently.
Company Profile and Achievements
INCOG BioPharma specializes in manufacturing sterile injectables, offering a robust portfolio of services, including the filling of drug products into vials, syringes, and cartridges. The company prioritizes customer experience and speed-to-market by focusing on forward-thinking project management and streamlined operational systems.
- 2022: Opened its first 90,000-square-foot manufacturing facility equipped with advanced cleanrooms and filling technologies to provide flexible fill-finish services for injectable products.
- 2023: Recognized as one of the Best Places to Work in Indiana, emphasizing its employee-centric culture.
- 2024: Introduced new capabilities and expanded its capacity with significant investments in infrastructure to support high-demand sterile product manufacturing.
Current Operations and Market Position
Currently, INCOG provides comprehensive CDMO services, excelling in sterile manufacturing for the biopharmaceutical industry. The company’s emphasis on integrated solutions and quality assurance has positioned it as a preferred partner for both startup and established pharmaceutical entities. With a focus on innovation, INCOG is expanding its facilities to support rising demand for injectables, ensuring it maintains competitive advantages and leading market share in the CDMO industry.
Conclusion
INCOG BioPharma Services has rapidly become a significant player in the CDMO sector, praised for its cutting-edge facilities and customer-focused services. Its investment in Fishers, Indiana, as part of a strategic hub for biopharmaceutical manufacturing, underscores its commitment to growth and industry leadership. As the demand for sterile injectables continues to rise, INCOG’s robust plans for expansion and capacity enhancement poise it for substantial future influence within the biopharma market.